Per WH, names and titles for attendees at POTUS roundtable with PhRMA execs
Note my first report misspelled name of Hugin [which is bad for a reporter from New Jersey]
Mr. Robert A. Bradway, Amgen; PhRMA Board of Directors
Mr. Joaquin Duato, Worldwide Pharmaceuticals, Johnson & Johnson; PhRMA Board of Directors
Mr. Kenneth C. Frazier, Merck; PhRMA Federal Committee
Mr. Robert J. Hugin, Celgene; PhRMA Public Affairs Committee
Mr. Joseph Jimenez, Novartis; PhRMA Board of Directors
Mr. David A. Ricks, Eli Lilly
Mr. Stephen J. Ubl, PhRMA
Chairman Greg Walden (OR-02), U.S. House of Representatives Committee on Energy and Commerce
A few more POTUS quotes
"We're going to be cutting regulations at a level nobody's ever seen before. And we're going to have tremendous protection for the people, maybe more protection."
"I'll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market. that includes price-fixing by the biggest dog in the market, Medicare, which is what's happening. But we can increase competition and bidding wars, big time."
"So what I want, we have to get lower prices, we have to get even better innovation and I want you to move your companies back into the United States. And I want you to manufacture in the United States. We're going to be lowering taxes, we're going to be getting rid of regulations that are unnecessary."
At the end of his remarks, POTUS invited attendees to go around the table and introduce themselves.
Hugin noted that Celgene operates in 15 countries around the world.
Bradway said Amgen was adding 1,600 jobs this year.
Ricks said Eli Lilly was "hiring manufacturing jobs as I speak."
Pooler could not hear Duato's remarks, but POTUS responded, "J&J. Good company."
Frazier noted that Merck has been in business 125 years, and has 23,000 American employees, and invested $7.5 billion in research and development, "almost all of it in the United States of Amercia." He also said the company was bringing manufacturing back for a new cancer drug
In a brief stop by the stake-out area, Frazier said the executives had a "great conversation" that focused on tax policies and making sure companies continue to innovate. He said they also talked about regulatory reform and how to make the marketplace work better.
Hugin said it was a positive meeting: "These changes are going to be great for the country," he said.